sorafenib has been researched along with oleanolic acid in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (oleanolic acid) | Trials (oleanolic acid) | Recent Studies (post-2010) (oleanolic acid) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 4,169 | 31 | 2,404 |
| Protein | Taxonomy | sorafenib (IC50) | oleanolic acid (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 2.045 | |
| Phospholipase A2 | Homo sapiens (human) | 3 | |
| DNA polymerase beta | Homo sapiens (human) | 6.8667 | |
| DNA polymerase beta | Rattus norvegicus (Norway rat) | 5.6 | |
| Receptor-type tyrosine-protein phosphatase C | Homo sapiens (human) | 1 | |
| Receptor-type tyrosine-protein phosphatase F | Homo sapiens (human) | 3.065 | |
| Tissue factor | Homo sapiens (human) | 0.005 | |
| Tyrosine-protein phosphatase non-receptor type 2 | Homo sapiens (human) | 4.38 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 2.8444 | |
| Liver carboxylesterase 1 | Homo sapiens (human) | 0.1 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 3.065 | |
| M-phase inducer phosphatase 2 | Homo sapiens (human) | 0.98 | |
| Dual specificity protein phosphatase 3 | Homo sapiens (human) | 5.4 | |
| Transcription factor p65 | Homo sapiens (human) | 2.4 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 3.065 | |
| Protease | Human immunodeficiency virus 1 | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abhari, BA; Fulda, S; Hinrichs, TM; Lange, M; Liese, J | 1 |
| Fulda, S; Hinrichs, TM; Lange, M; Liese, J | 1 |
2 other study(ies) available for sorafenib and oleanolic acid
| Article | Year |
|---|---|
Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Caspase Inhibitors; Cell Death; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Drug Synergism; Enzyme Activation; Free Radical Scavengers; Humans; Liver Neoplasms; Niacinamide; Oleanolic Acid; Oxidative Stress; Phenylurea Compounds; Proteolysis; Reactive Oxygen Species; Sorafenib | 2016 |
Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Therapy, Combination; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Oleanolic Acid; Reactive Oxygen Species; Sorafenib; Tumor Cells, Cultured | 2019 |